TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Monash IVF Group Ltd ( (AU:MVF) ) just unveiled an update.
Monash IVF Group reported a 6.7% increase in revenue and a 5.6% rise in underlying EBITDA for FY25, despite facing challenges such as a softened fertility sector and adverse incidents at two clinics. The company has implemented enhanced safety protocols and conducted an independent review to address these issues. Although no final dividend was declared for FY25 due to settlement payments and softer trading conditions, the company plans to resume dividends in FY26. Monash IVF is undergoing leadership changes, with Dr. Victoria Atkinson set to become the new CEO in May 2026, and is focusing on governance and sustainability practices to ensure long-term growth and value creation.
The most recent analyst rating on (AU:MVF) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.
More about Monash IVF Group Ltd
Monash IVF Group Ltd operates within the fertility industry, providing a range of services including IVF treatments, diagnostics, and day hospital facilities. The company has a strong presence in Australia with 24 IVF clinics and international operations in Malaysia, Singapore, and Bali. Monash IVF is focused on delivering comprehensive fertility solutions and enhancing patient care through its integrated diagnostics platform.
Average Trading Volume: 2,525,319
Technical Sentiment Signal: Sell
Current Market Cap: A$233.8M
For a thorough assessment of MVF stock, go to TipRanks’ Stock Analysis page.